Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection
SARS-CoV-2 감염 이전에 BNT162b2 mRNA COVID-19 백신에 대한 항체 반응
Clinical Trial
[키워드] all subject
all subjects
analyzed
Anti-spike
anti-spike RBD IgG antibody
antibody
antibody levels
Antibody Response
Antibody titers
BNT162b2
BNT162b2 mRNA
BNT162b2 mRNA COVID-19 vaccine
booster
both groups
control subject
COVID-19
COVID-19 vaccine
COVID-19 vaccines
decrease
develop
domain
effective response
expected
first dose
Frequency
healthcare worker
IgG antibodies
IgG antibody
immune memory
immune memory persist
immune response
immunogenicity
individual
induce
infected individuals
Infection
local pain
naïve individuals
naïve subject
naïve subjects
natural infection
Neutralizing antibodies
neutralizing antibody
Neutralizing antibody titer
neutralizing antibody titers
nine
no significant difference
not significantly different
pre-existing immunity
rapid increase
RBD
reactogenicity
response
SARS-CoV-2
SARS-COV-2 infection
Side effects
single dose
subjects
sustained
the antibody response
the vaccine
titers
vaccination
Vaccine
vaccine dose
vaccine doses
vaccine-associated side effects
[DOI] 10.3390/v13030422 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.3390/v13030422 PMC 바로가기 [Article Type] Clinical Trial